Esperion Shares Surge on Cholesterol Drug Applications in Canada

Shares of Esperion Therapeutics rose by as much as 23% on Monday. This notable increase, marking the largest intraday gain seen in nearly a year, came after the company announced it had submitted New Drug Applications (NDA) to Health Canada for its two cholesterol therapies, Nexletol and Nexlizet. The company's strategic efforts to expand the availability of its products in various markets have been appreciated by industry analysts. Joseph Pantginis, an analyst at HC Wainwright, commented on Esperion's recent moves, stating that the company's focus on expanding access to cholesterol treatments in both established and emerging markets positions it well for meaningful long-term growth.